Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Key insights from The Atlantic: 14 million adults on Medicaid suffer from obesity, but only 13 states currently cover GLP-1s for weight management These drugs reduce weight by 15-20% and show benefits for diabetes, cardiovascular disease, liver/kidney disease, and even substance abuse Budget fears may be overblown: with Medicaid negotiation power and falling prices, costs could be offset by 27%+ through reduced healthcare spending At projected Medicaid prices (~$235/month), covering 10% of eligible patients would increase Medicaid spending by just 0.4% For communities like zip code 78207 facing a diabetes crisis, this isnt just about weight lossits about access to life-saving medication that could add 3-4 years to life expectancy while reducing complications from multiple chronic conditions
So how did I get wrapped up in the world of GLPs
Reddy's Laboratories has received approval to manufacture generic Semaglutide, opening access to the rapidly expanding GLP-1 weight-loss and diabetes market
It seems as research continues to unfold, the conversation around GLPs is becoming less about aesthetics and more about long-term health, resilience, and quality of life, and I AM HERE FOR IT!
Lees, P
